ALEMTUZUMAB BUDGET IMPACT ANALYSIS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE US

被引：0
|
作者：
Celestin, C. [1 ]
Wandstrat, T. [1 ]
Coleman, C., I [2 ]
机构：
[1] Genzyme, Cambridge, MA USA
[2] Univ Connecticut, Hartford Hosp, Evidence Based Practice Ctr, Hartford, CT 06112 USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jval.2015.03.1637
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND17
引用
收藏
页码：A280 / A280
页数：1
相关论文
共 50 条
  • [1] BUDGET IMPACT MODELLING FOR ALEMTUZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS IN COLOMBIA
    Londono, S.
    Gomez, N.
    [J]. VALUE IN HEALTH, 2020, 23 : S625 - S625
  • [2] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797
  • [3] Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Hersh, Carrie M.
    Cohen, Jeffrey A.
    [J]. IMMUNOTHERAPY, 2014, 6 (03) : 249 - 259
  • [4] BUDGET IMPACT ANALYSIS OF ALEMTUZUMAB IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN HEALTHCARE SOCIAL SECURITY (ESSALUD) IN PERU
    Moreno, M.
    Arce, J.
    Cruz, A.
    Carpio Farro, R.
    [J]. VALUE IN HEALTH, 2020, 23 : S265 - S265
  • [5] Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis
    Brown, J. William L.
    Coles, Alasdair J.
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2013, 7 : 131 - 138
  • [6] Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis
    Gomez, Pablo Rodriguez de Vera
    Muros, Mariola Mendez
    Cuadro, Alberto Torres
    de Miera, Francisco Javier Toyos Saenz
    Ruiz, Rocio Lopez
    Vazquez, Raquel Guerrero
    Gonzalez, Juan Jesus Garcia
    Hermosilla, Antonio Manuel Garrido
    Hernandez, Tomas Martin
    [J]. JOURNAL OF NEUROLOGY, 2024, 271 (01) : 486 - 496
  • [7] COST-EFFECTIVENESS OF ALEMTUZUMAB FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Kohn, Christine G.
    Costales, Victoria
    Coleman, Craig I.
    Young, Dan
    Limone, Brendan L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (10) : 1413 - 1414
  • [8] Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis
    Hartung, Hans-Peter
    Aktas, Orhan
    Boyko, Alexey N.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (01) : 22 - 34
  • [9] Autoimmunity in patients treated with alemtuzumab for relapsing-remitting multiple sclerosis
    Fox, E. J.
    Arnold, D. L.
    Cohen, J.
    Coles, A. J.
    Confavreux, C.
    Hartung, H. -P.
    Havrdova, E.
    Selmaj, K.
    Weiner, H.
    Lake, S. L.
    Margolin, D. H.
    Oyuela, P.
    Panzara, M.
    Compston, D. A. S.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 465 - 466
  • [10] Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis
    Ranganathan, Usha
    Kaunzner, Ulrike
    Foster, Stacyann
    Vartanian, Timothy
    Perumal, Jai S.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (04) : 553 - 554
12345